Actively Recruiting
Mifepristone Outpatient Labour Induction
Led by Chelsea and Westminster NHS Foundation Trust · Updated on 2025-09-10
400
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The number of women having an induction of labour is increasing and is currently used in 33% of pregnancies for a range of medical reasons. The majority of women are admitted to hospital to have their labour induced, using methods which are protracted and associated with a poor birth experience, making them both costly and unpopular. Further, current methods of outpatient induction are unsuitable, unsafe and/or have a poor acceptability. The COVID-19 pandemic has driven a reduction in the number of face-to-face interactions taking place across all areas of medicine. Proving the efficacy and safety of Mifepristone would significantly reduce pre-labour admission rates and hospital length of stay for pregnant women, who are at particularly higher risk of COVID-19, and reduce delivery costs.
CONDITIONS
Official Title
Mifepristone Outpatient Labour Induction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnant women between 36 weeks and 5 days and 41 weeks and 5 days of gestation
- Singleton pregnancy
- Aged 18 years or older
- Unfavourable cervix with Bishop Score less than or equal to 6
- Ability to understand and sign informed consent and willingness to follow all study procedures
You will not qualify if you...
- Breech fetal presentation
- Early labour
- Contraindications to vaginal birth such as placenta praevia, transverse lie, or suspected cephalo-pelvic disproportion
- Fetal growth restriction with oligohydramnios or abnormal Dopplers
- Reduced fetal movements needing urgent delivery, abnormal CTG, or recent antepartum hemorrhage requiring immediate delivery
- Active sexually transmitted infections
- Bleeding disorders or current use of anticoagulants, steroids, or aspirin
- Prior uterine surgery including Caesarean section or myomectomy
- Contraindications to mifepristone including chronic adrenal, liver, or kidney failure
- Hypersensitivity to mifepristone or excipients, or malnutrition
- Severe uncontrolled asthma and inherited porphyria
- Use of investigational drugs interacting with mifepristone within 30 days prior to trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chelsea and Westminster Hospital
London, United Kingdom
Actively Recruiting
Research Team
T
Tess Cheetham
CONTACT
A
Arnold Xhikola
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here